L. Becker Hewes Net Worth

The estimated Net Worth of L. Becker Hewes is at least $9.13 Millón dollars as of 4 June 2024. L Hewes owns over 2,424 units of Blueprint Medicines Corp stock worth over $2,554,732 and over the last 4 years L sold BPMC stock worth over $6,580,157.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

L Hewes BPMC stock SEC Form 4 insiders trading

L has made over 13 trades of the Blueprint Medicines Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently L sold 2,424 units of BPMC stock worth $254,302 on 4 June 2024.

The largest trade L's ever made was selling 39,030 units of Blueprint Medicines Corp stock on 31 May 2024 worth over $4,136,399. On average, L trades about 4,142 units every 65 days since 2021. As of 4 June 2024 L still owns at least 29,514 units of Blueprint Medicines Corp stock.

You can see the complete history of L Hewes stock trades at the bottom of the page.

What's L Hewes's mailing address?

L's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Blueprint Medicines Corp

Over the last 10 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr y Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.

What does Blueprint Medicines Corp do?

blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development

Complete history of L Hewes stock trades at Blueprint Medicines Corp

Blueprint Medicines Corp executives and stock owners

Blueprint Medicines Corp executives and other stock owners filed with the SEC include:

• Jeffrey Albers,
  Chief Executive Officer, Director
• Christina Rossi,
  Chief Commercial Officer
• Christopher Murray,
  Senior Vice President, Technical Operations
• Kathryn Haviland,
  Chief Operating Officer
• Tracey McCain,
  Chief Legal Officer, Chief Compliance Officer
• Marion Dorsch,
  Chief Scientific Officer
• Anthony Boral,
  Chief Medical Officer
• Michael Landsittel,
  Chief Financial Officer
• Jeffrey W. Albers J.D., M.B.A., MBA,
  Chairman, CEO & Pres
• Jeffrey W. Albers M.B.A., J.D., MBA,
  CEO, Pres & Director
• Kathryn Haviland,
  Chief Operating Officer
• Tracey L. McCain Esq.,
  Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec.
• Dr. Fouad Namouni M.D.,
  Pres of R&D
• Tracey L. Mccain,
  Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec.
• Michael Landsittel,
  CFO & Treasurer
• Daniel Lynch,
  Independent Chairman of the Board
• Nicholas Lydon,
  Independent Director
• Charles Rowland,
  Independent Director
• George Demetri,
  Independent Director
• Lonnel Coats,
  Independent Director
• Lynn Seely,
  Independent Director
• Mark Goldberg,
  Independent Director
• Alexis Borisy,
  Director
• Alexis A. Borisy A.M.,
  Co-Founder & Director
• Fouad Namouni,
  President, Research & Development
• Debra Durso-Bumpus,
  Chief Human Resource Officer
• Kristin Hodous,
  IR Contact Officer
• Ariel Hurley,
  Vice President - Finance, Controller
• Dr. Percy H. Carter M.B.A., Ph.D.,
  Chief Scientific Officer
• Dr. Christopher K. Murray,
  Sr. VP of Technical Operations
• Ariel Hurley,
  Principal Accounting Officer, VP of Fin. & Controller
• Debra Durso-Bumpus,
  Chief People Officer
• Dr. Fouad Namouni,
  Pres of R&D
• Mark J Levin,
  10% owner
• Rock Ventures Ii, L.P.Third...,
  
• Kevin P Starr,
  10% owner
• Habib J Dable,
  
• John Tsai,
  
• Daniella Beckman,
  
• Christoph Lengauer,
  Chief Scientific Officer
• L. Becker Hewes,
  CHIEF MEDICAL OFFICER
• Percy H. Carter,
  CHIEF SCIENTIFIC OFFICER
• Therapeutics, Inc. Tango,
  Director
• Kate Haviland,
  CHIEF EXECUTIVE OFFICER
• Philina Lee,
  CHIEF COMMERCIAL OFFICER